Completed PHASE2 INTERVENTIONAL 1-arm NCT00003459

Antineoplaston Therapy in Treating Patients With Brain Stem Glioma

Phase II Study of Antineoplastons A10 and AS2-1 In Patients With Brain Stem Glioma

Sponsor: Burzynski Research Institute

Interventions Antineoplaston therapy (Atengenal + Astugenal)

Updated 8 times since 2017 Last updated: Mar 11, 2018 Started: Mar 31, 1996 Primary completion: Sep 30, 2007 Completion: Sep 30, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Brain Stem Gliomas and is currently completed. Burzynski Research Institute leads this study, which shows 8 recorded versions since 1996 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2023 — Jul 2024 [monthly]

Completed PHASE2
Dec 2022 — Jan 2023 [monthly]

Completed PHASE2
Jan 2021 — Dec 2022 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Mar 1996

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Burzynski Research Institute

Data source: Burzynski Research Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Houston, United States